ERBB2 and triple-negative breast carcinoma: Although not significant, the MD Anderson-Metastatic Breast-231 (MDA-MB-231) triple negative breast cancer (TNBC) cells had a higher susceptibility to the individual cannabinoid treatments when compared to the Michigan Cancer Foundation-7 (MCF-7) breast cancer cells (ER+, PR+, and HER2+), as indicated by the inhibitory concentrations (Table 1).